MedPath

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia

Dr. Jorge E. Cortes presents the 5-year follow-up results from the Phase 2 OPTIC study, highlighting the long-term efficacy, safety, and mutational analysis of ponatinib in treating chronic-phase chronic myeloid leukemia.

Dr. Jorge E. Cortes provides a comprehensive overview of the 5-year follow-up results from the Phase 2 OPTIC study, showcasing the long-term efficacy, safety, and mutational analysis of ponatinib in patients with chronic-phase chronic myeloid leukemia, including outcomes related to dose modifications and mutation evolution.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

LUMEVOQ Gene Therapy Shows Sustained Vision Improvement in LHON Patients After 5 Years

GenSight Biologics' LUMEVOQ demonstrates sustained visual acuity improvement in Leber Hereditary Optic Neuropathy (LHON) patients five years post-treatment.
Bilateral injections of LUMEVOQ resulted in a higher rate of clinically relevant visual recovery compared to unilateral treatment in the REFLECT Phase III trial.

Lenadogene Nolparvovec Shows Sustained Vision Improvement in LHON Patients After 5 Years

A 5-year follow-up study (RESTORE) showed that lenadogene nolparvovec gene therapy provides sustained visual acuity improvement in both eyes of LHON patients with the MT-ND4 mutation.
The study demonstrated a mean change in BCVA of -0.4 logMAR (more than +4 lines) in treated eyes, similar to sham-treated eyes, indicating a potential bilateral therapeutic effect.

Risk Management Strategies Improve Long-Term Safety Profile of Ponatinib in CML and ALL

A 10-year retrospective study reveals that implementing risk management measures significantly reduced adverse events associated with ponatinib (Iclusig) in ALL and CML patients.
Reporting rates of important identified risks (IIRs) decreased from 2.369 in 2013 to 0.219 in 2022, demonstrating the effectiveness of post-approval safety interventions.

Olverembatinib Shows Promise as Second-Line Therapy for Chronic Phase CML

Olverembatinib demonstrates notable efficacy in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to first-line TKIs.
The study showed that 74.1% of efficacy-evaluable patients achieved complete cytogenetic response (CCyR), and 40.6% experienced major molecular response (MMR).

PolyActiva's PA5108 Glaucoma Implant Demonstrates Promising IOP Reduction in Phase 2 Trial

PolyActiva's PA5108 implant showed significant IOP reduction over 26 weeks in a Phase 2 trial, meeting key efficacy and safety endpoints.
The implant, designed for sustained latanoprost delivery, addresses patient adherence issues by providing consistent medication over an extended period.

Nanoscope's MCO-010 Gene Therapy Shows Sustained Vision Improvement in Retinitis Pigmentosa Trial

Nanoscope Therapeutics' MCO-010 gene therapy significantly improved visual acuity in retinitis pigmentosa patients compared to the control group in a Phase 2b trial.
The RESTORE trial demonstrated statistically significant and durable vision improvement over a two-year period, with some patients showing clinically meaningful gains.

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia

A 5-year follow-up of the Phase 2 Optic Study reveals insights into the efficacy, safety, and first end-of-treatment mutational results for patients with chronic-phase chronic myeloid leukemia.

Tailored TKI Dosing Strategies Improve Outcomes in Chronic Myeloid Leukemia

Tailored dosing of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) improves safety without compromising efficacy, according to Elias Jabbour, MD.
The phase 4 BYOND trial demonstrated that bosutinib is effective with sustained responses and manageable adverse effects in TKI-pretreated CML patients.

Ponatinib Dose-Ranging Study Shows Efficacy in Chronic-Phase CML Patients

A phase 2 trial evaluating ponatinib in chronic-phase chronic myeloid leukemia (CP-CML) patients resistant to prior tyrosine kinase inhibitors (TKIs) demonstrated significant efficacy across three starting doses. The study highlighted a novel, response-based dose-reduction strategy, with the 45 mg starting dose showing optimal benefit/risk outcomes when reduced to 15 mg upon achieving a response.

Final 5-Year Results of the Phase 2 PACE Trial for CML and Ph+ ALL Patients

The PACE trial's final 5-year results demonstrate ponatinib's efficacy and safety in treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients who have undergone prior therapies. The study highlights significant response rates, durability of responses, and the impact of dose adjustments on maintaining efficacy while managing adverse events.

Reference News

[1]
5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic ...
onclive.com · Jan 14, 2025

Dr. Jorge E. Cortes highlights the 5-year OPTIC study results, detailing ponatinib's long-term efficacy, safety, and mut...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy